United Therapeutics Corporation Debt Securities, Available-for-sale, Unrealized Loss Position
United Therapeutics Corporation (UTHR) had Debt Securities, Available-for-sale, Unrealized Loss Position of $1.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.33B.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $942.20M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $238.10M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $379.20M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $1.33B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $942.20M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $238.10M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $379.20M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $1.10B 10-Q · filed 2025-07-30 |
| 2025-03-31 | $926.00M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $1.45B 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.05B 10-Q · filed 2024-10-30 |
| 2024-06-30 | $2.70B 10-Q · filed 2024-07-31 |
| 2024-03-31 | $2.61B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $2.43B 10-K · filed 2025-02-26 |
| 2023-09-30 | $3.66B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $3.59B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.47B 10-Q · filed 2023-05-03 |
| 2022-12-31 | $2.96B 10-K · filed 2024-02-21 |
| 2022-09-30 | $3.08B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $2.81B 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.61B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $2.08B 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |